文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

乙酰水杨酸治疗脓毒症与脓毒性休克患者:一项2期、安慰剂对照、随机临床试验

Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial.
PubMed 文献 · Crit Care Med · 2025-02-21
一句话结论脓毒症患者使用乙酰水杨酸200 mg×7天未减轻器官功能障碍,反而增加严重出血风险,试验因出血事件提前终止。

这项在巴西5个综合ICU开展的随机、盲法、平行组、安慰剂对照2期试验,纳入脓毒症病程不超过48小时且至少存在一项严重器官功能障碍的成人患者。患者随机接受乙酰水杨酸200 mg或安慰剂治疗7天。主要终点为第0天至第7天(或出院/死亡日)SOFA评分变化,计划样本量218例,因乙酰水杨酸组大出血发生频率更高而提前终止,实际纳入166例(乙酰水杨酸组82例,安慰剂组84例)。校正分析显示两组SOFA评分变化无差异(安慰剂组与乙酰水杨酸组均值差0.60,95%CI -0.55至1.75,p=0.30),乙酰水杨酸组严重不良事件更多(9例[11%] vs 1例[1.2%],p=0.009),大出血更多(8例[8.5%] vs 1例[1.2%],p=0.02)。

要点

  • 乙酰水杨酸200 mg×7天未减轻脓毒症患者器官功能障碍:安慰剂组与乙酰水杨酸组SOFA评分变化均值差0.60(95%CI -0.55至1.75,p=0.30),无差异。
  • 乙酰水杨酸组大出血8例(8.5%)vs 安慰剂组1例(1.2%),p=0.02,试验因此提前终止。
  • 乙酰水杨酸组严重不良事件9例(11%)vs 安慰剂组1例(1.2%),p=0.009。
  • 主要终点为第0天至第7天或出院/死亡日的SOFA评分变化,所有次要终点均无差异。
  • 研究纳入脓毒症病程不超过48小时、至少一项严重器官功能障碍(乳酸>4 mmol/L、血小板<100,000/mm3、PaO2/FiO2<200或脓毒性休克)的成人患者。

适用人群与场景

  • 巴西5个综合ICU的成人脓毒症患者,脓毒症病程不超过48小时,且至少存在一项严重器官功能障碍:乳酸>4 mmol/L、血小板<100,000/mm3、PaO2/FiO2<200或脓毒性休克。

诊断标准与关键阈值

  • 严重器官功能障碍标准:乳酸>4 mmol/L、血小板<100,000/mm3、PaO2/FiO2<200或脓毒性休克。
  • 脓毒症病程不超过48小时。

处置流程与药物剂量

  • 乙酰水杨酸200 mg或安慰剂,治疗7天。

研究设计与关键结果

  • 研究设计:随机、盲法、平行组、安慰剂对照2期试验,在巴西5个综合ICU开展。
  • 计划样本量218例,计划在纳入109例和163例后进行中期安全性分析;因乙酰水杨酸组大出血频率更高,研究提前终止。
  • 实际纳入166例:乙酰水杨酸组82例,安慰剂组84例。
  • 主要终点(第0天至第7天或出院/死亡日的SOFA评分变化):校正分析显示两组无差异,安慰剂组与乙酰水杨酸组均值差0.60(95%CI -0.55至1.75,p=0.30)。
  • 所有次要终点均无差异。
  • 严重不良事件:乙酰水杨酸组9例(11%)vs 安慰剂组1例(1.2%),p=0.009。
  • 大出血:乙酰水杨酸组8例(8.5%)vs 安慰剂组1例(1.2%),p=0.02。

证据类型、等级与局限

  • 证据类型:随机、盲法、平行组、安慰剂对照2期临床试验。
  • 因乙酰水杨酸组大出血频率更高,研究提前终止。

对床旁实践的改变

  • 在脓毒症病程不超过48小时且至少一项严重器官功能障碍的成人患者中,乙酰水杨酸200 mg×7天未减轻器官功能障碍,反而增加严重出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Platelets play a critical role in the inflammatory response and coagulation. We aimed to evaluate whether the use of acetylsalicylic acid (ASA) would reduce the intensity of organ dysfunction in septic patients.

DESIGN: Randomized, blinded, parallel-group, placebo-controlled trial.

SETTING: Five general ICUs in Brazil.

PATIENTS: Adults with sepsis for no longer than 48 hours who had at least one severe organ dysfunction (lactate > 4 mmol/L, platelets < 100,000/mm3, Pao2/Fio2 ratio < 200, or septic shock).

INTERVENTIONS: Patients were randomized to receive 200 mg of ASA or placebo for 7 days.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score between day 0 and day 7 or date of discharge/death. Safety outcomes were major bleeding and the number of blood transfusions within 14 days. The planned sample size was 218 with interim safety analyses after enrolling 109 and 163 patients. The study was discontinued due to higher frequency of major bleeding in the ASA group. We included 166 patients (ASA: 82 patients, placebo: 84). In the adjusted analysis, there was no difference in the SOFA change between the groups (mean placebo to ASA group difference, 0.60; 95% CI, -0.55 to 1.75; p = 0.30). There were no differences in any of the secondary outcomes. In the intervention group, there were a higher number of serious adverse events (9 [11%] vs. 1 [1.2%]; p = 0.009) and major bleeding (8 [8.5%] vs. 1 [1.2%]; p = 0.02).

CONCLUSIONS: In this population of septic patients, ASA did not reduce the intensity of organ dysfunction. ASA increased the risk of severe bleeding compared with placebo.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Almeida TML, Freitas FGR, Figueiredo RC, et al. Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial. Crit Care Med. 2025. PMID: 39982179. doi:10.1097/CCM.0000000000006564

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。